Trump eyes 100% drug tariffs

Drug tariffs are now a real policy, not just a Trump threat. On April 2, the White House rolled out Section 232 tariffs on patented pharmaceuticals and their ingredients, with the headline rate set at 100% for covered imports. But the catch is that almost nobody will simply pay a flat 100% tomorrow. This is a tiered pressure system — part trade barrier, part industrial policy, part drug-pricing squeeze. (whitehouse.gov) ### What actually got tariffed? Patented drugs, biologics, and the active ingredients used to make them are the main targets. The administration tied the move to Section 232 — the national-security trade law Trump has been using more aggressively after courts knocked out some broader tariff tools. In plain English, the argument is that the US relies too heavily on foreign-made brand-name medicines and key inputs. (whitehouse.gov) ### Is it really a 100% tariff? Yes — but only as the top rate. The White House fact sheet says 100% applies to patented pharmaceutical products and ingredients, with the tariff taking effect in 120 days for cert(whitehouse.gov)number is real, but the rollout is staggered. (whitehouse.gov) ### Who can avoid the full hit? This is where the policy gets weirdly transactional. Companies that sign both most-favored-nation drug-pricing deals with HHS and onshoring agreements with Commerce can get a 0% ta(whitehouse.gov)two things at once — lower US prices and more US manufacturing. (whitehouse.gov) ### Are all foreign drugs treated the same? No. Imports from the EU, Japan, South Korea, Switzerland, and Liechtenstein get a 15% rate instead of the general 100% rate. The UK gets separate treatment tied to its (whitehouse.gov)eatment, and everyone else gets the hammer. (whitehouse.gov) ### What’s exempt? A lot more than the headline suggests. Generic drugs and biosimilars are out for now. So are orphan drugs and a long list of specialty products — things like animal-health medicines, some cell (whitehouse.gov)es than at the whole drug supply. (whitehouse.gov) ### Why does that matter for patients? Because branded drugs are where the money is. If a blockbuster patented medicine is imported and the manufacturer does not cut a deal, the tariff can become a giant extra co(whitehouse.gov)he company, insurers, employers, or patients. That uncertainty is why pharma and markets reacted so nervously. (whitehouse.gov) ### Why use Section 232 for this? Because Section 232 gives Trump a narrower but sturdier legal lane. It lets the administration frame imports as a national-security problem rather than just a trade imbalance. Th(whitehouse.gov)ouches both supply chains and healthcare costs. (whitehouse.gov) ### Bottom line The clean version is simple: Trump is not just “eyeing” 100% drug tariffs anymore — he authorized them on April 2. But the real mechanism is more strategic than the headline. This is a conditional tariff regime designed to make drugmakers choose between paying up, cutting prices, or moving production into the US. (whitehouse.gov)